February 28, 2017 / 9:18 PM / 5 months ago

BRIEF-Ligand expands license with Sermonix

1 Min Read

March 1 (Reuters) - Ligand Pharmaceuticals Inc

* Ligand expands license with Sermonix to include worldwide rights for oral lasofoxifene

* Ligand Pharmaceuticals Inc says amendment includes an upfront payment, additional commercial milestones and 6% to 10% royalties on ex-us sales Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below